# US 2018/0022805 A1 · Anti-pre-bcr antagonists and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022805 A1
- Document ID: US20180022805A1
- Status: Published application
- Kind: A1
- Application number: 15/548,871
- Filed: 2016-02-05
- Published: 2018-01-25
- Earliest claimed: 2015-02-05
- Assignees: Stc.Unm
- Applicants: Stc.Unm
- Inventors: Bridget S. Wilson; Stuart S. Winter; Michael Frank Erasmus; Michael Horowitz
- Web page: https://patentgrep.com/patent/US20180022805A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/02: specific for leukemia
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.

## Claims

### Claim 1

A composition comprising:
a pre-B cell receptor (pre-BCR) antagonist that is engineered for expression as a T cell chimeric receptor.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the pre-BCR antagonist comprises an antibody that specifically binds to pre-BCR.

### Claim 3 (depends on 2)

The composition of claim 2 wherein the antibody comprises an antibody fragment.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the antibody fragment comprises a monovalent antibody.

### Claim 5 (depends on 4)

The composition of claim 4 wherein the monovalent antibody comprises a scFv or Fab-Fc.

### Claim 6 (depends on 2)

The composition of claim 2 wherein the antibody is humanized.

### Claim 7 (depends on 2)

The composition of claim 2 wherein the antibody comprises an anti-VpreB antibody.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the anti-VpreB antibody comprises anti-VpreB1 antibody.

### Claim 9 (depends on 1)

The composition of claim 1 wherein the antagonist is recombinant.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising:
the composition of claim 1; and
a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

A method comprising:
administering to a subject having B cell precursor acute lymphoblastic leukemia (BCP-ALL) the composition of claim 1 in an amount effective to ameliorate at least one symptom or clinical sign of BCP-ALL.

### Claim 12 (depends on 1)

A kit comprising the composition of claim 1.
